NeuroBo Pharmaceuticals Files Definitive Proxy Statement

TL;DR

NeuroBo Pharma (NRBO) filed its DEF 14A proxy statement. Standard stuff, but check for shareholder meeting details.

AI Summary

NeuroBo Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 21, 2024, for its fiscal year ending December 31, 2024. The company, formerly known as Gemphire Therapeutics Inc., is based in Cambridge, MA, and operates in the pharmaceutical preparations industry. This filing is a standard procedural document related to shareholder meetings and corporate governance.

Why It Matters

This filing provides shareholders with essential information regarding corporate governance and upcoming decisions, allowing them to make informed voting choices at shareholder meetings.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain new financial or operational disclosures that would immediately impact risk.

Key Numbers

• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)

Key Players & Entities

• NeuroBo Pharmaceuticals, Inc. (company) — Registrant
• Gemphire Therapeutics Inc. (company) — Former company name
• 20240821 (date) — Filing date
• 20240918 (date) — Period of report
• 0001140361-24-038067 (document_id) — Accession Number

FAQ

Key Financial Figures

• $0.001 — r shares of our common stock, par value $0.001 per share (the "Common Stock" ). Instea
• $3.93 — ur Common Stock, at a purchase price of $3.93 per share (the "Registered Direct Offer
• $3.0 million — eceived gross proceeds of approximately $3.0 million before deducting the Placem

Filing Documents

• ny20032269x2_def14a.htm (DEF 14A) — 187KB
• logo_neurobo.jpg (GRAPHIC) — 50KB
• ny20032269x1_pc01.jpg (GRAPHIC) — 665KB
• ny20032269x1_pc02.jpg (GRAPHIC) — 430KB
• sig_andrewkoven.jpg (GRAPHIC) — 34KB
• 0001140361-24-038067.txt ( ) — 1811KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 13 ADDITIONAL INFORMATION 15 HOUSEHOLDING 16 AVAILABLE INFORMATION 16 OTHER MATTERS 17 TABLE OF CONTENTS NeuroBo Pharmaceuticals, Inc. 545 Concord Avenue, Suite 210 Cambridge, Massachusetts 02138 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS GENERAL INFORMATION ABOUT THE MEETING Our Board of Directors (the "Board" ) solicits your proxy on our behalf for the special meeting of stockholders (the "Special Meeting" ) and at any postponement or adjournment of the Special Meeting for the purposes set forth in this proxy statement (the "Proxy Statement" ) and the accompanying Notice of Special Meeting of Stockholders (the "Notice" ). The Special Meeting will be held on Wednesday, September 18, 2024, at 1:00 p.m. Eastern Time, as a virtual meeting at www.virtualshareholdermeeting.com/NRBO2024SM. The foregoing items of business are more fully described in the Proxy Statement accompanying this notice. This Proxy Statement is first being sent to the Company's stockholders on or about August 21, 2024. Unless we state otherwise or the context otherwise requires, references in this Proxy Statement to "we," "us," "the Company" and "our" refer to NeuroBo Pharmaceuticals, Inc., a Delaware corporation. We encourage you to vote your shares of Common Stock (as defined below), either by attending the virtual Special Meeting or by granting a proxy (i.e., authorizing someone to vote your shares of Common Stock). If you vote via the Internet or telephone or execute the attached proxy card, the individuals designated will vote your shares of Common Stock according to your instructions. Purpose of the Meeting We are holding the Special Meeting in order to seek stockholder approval, in accordance with the applicable rules of the Nasdaq Capital Market ( "Nasdaq" ), for: Proposal 1 – the issuance of shares of our common stock, par value $0.001 per share (the "Common Stock" ), in an amount equa

View Full Filing

View this DEF 14A filing on SEC EDGAR